Disclosure statement
No potential conflict of interest was reported by the author(s).
Additional information
Funding
The author(s) reported there is no funding associated with the work featured in this article.
Leukemia & Lymphoma
Volume 64, 2023 - Issue 14
Letters to the Editor
Disease response upon cessation of methotrexate in a patient with Hodgkin lymphoma treated with pembrolizumab
Robert Stuvera Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USACorrespondence[email protected]
https://orcid.org/0000-0003-0991-5170View further author information
https://orcid.org/0000-0003-0991-5170View further author information, , Akshay Bedmuthab Department of Radiology, Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USAhttps://orcid.org/0000-0001-5683-4918View further author information
https://orcid.org/0000-0001-5683-4918View further author information, Karmela Kim Chanc Hospital for Special Surgery, New York, NY, USAhttps://orcid.org/0000-0001-8619-8588View further author information
https://orcid.org/0000-0001-8619-8588View further author information, , , & show all![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})